A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
The purpose of this study is to identify at least one dose of BMS-986001 which is safe, well tolerated, and efficacious when combined with Efavirenz (EFV) + Lamivudine (3TC) for treatment-naive Human Immunodeficiency Virus 1 (HIV-1) infected subjects
Double Blind through Week 24. Partially Blind (to subjects, caregivers, Investigators) through Week 48.
Inclusion Criteria:
Exclusion Criteria:
Washingtondc, Maryland 20009, United States
Ciudad de Buenos Aires, Buenos Aires C1426EGR, Argentina
Bogota, Cundinamarca, Colombia
Cercado, Lima 1, Peru
Durban KZN, 4001, South Africa
Nontaburi, 11000, Thailand